|
US2677682A
(en)
|
1951-08-24 |
1954-05-04 |
American Cyanamid Co |
Sulfonamido pteridines
|
|
ID18983A
(id)
|
1996-12-04 |
1998-05-28 |
Lilly Co Eli |
Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
|
|
SE0001899D0
(sv)
|
2000-05-22 |
2000-05-22 |
Pharmacia & Upjohn Ab |
New compounds
|
|
ES2234451T1
(es)
|
2001-11-14 |
2005-07-01 |
Teva Pharmaceutical Industries Ltd. |
Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion.
|
|
JP4869072B2
(ja)
|
2003-11-14 |
2012-02-01 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール
|
|
MXPA06008606A
(es)
|
2004-01-30 |
2007-04-13 |
Vertex Pharma |
Moduladores de transportadores con casete de union a atp.
|
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
LT2502911T
(lt)
|
2004-06-24 |
2017-09-11 |
Vertex Pharmaceuticals Incorporated |
Atp surišančios kasetės transporterių moduliatoriai
|
|
ATE512145T1
(de)
|
2005-08-11 |
2011-06-15 |
Vertex Pharma |
Modulatoren des cystic fibrosis transmembrane conductance regulators
|
|
WO2007053641A2
(en)
|
2005-11-01 |
2007-05-10 |
Mars, Incorporated |
A-type procyanidins and inflammation
|
|
AU2006331565A1
(en)
|
2005-12-27 |
2007-07-05 |
Vertex Pharmaceuticals Incorporated |
Compounds useful in CFTR assays and methods therewith
|
|
AU2006336504C9
(en)
|
2005-12-28 |
2015-05-14 |
Vertex Pharmaceuticals Incorporated |
1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
|
|
US7671221B2
(en)
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
WO2007079139A2
(en)
|
2005-12-28 |
2007-07-12 |
Vertex Pharmaceuticals, Inc. |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
NZ571803A
(en)
|
2006-04-07 |
2011-12-22 |
Vertex Pharma |
Amide indole derivatives as modulators of ATP-binding cassette transporters
|
|
EP2021797B1
(en)
|
2006-05-12 |
2011-11-23 |
Vertex Pharmaceuticals, Inc. |
Compositions of n-ý2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl¨-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
CA2668305C
(en)
|
2006-11-03 |
2017-01-03 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as cftr modulators
|
|
MX2009013213A
(es)
|
2007-06-08 |
2010-03-30 |
Abbott Lab |
Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa.
|
|
WO2009038683A2
(en)
|
2007-09-14 |
2009-03-26 |
Vertex Pharmaceuticals Incorporated |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
EP2639224B1
(en)
|
2007-12-07 |
2016-08-24 |
Vertex Pharmaceuticals Incorporated |
Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
|
|
SI2225230T1
(sl)
|
2007-12-07 |
2017-03-31 |
Vertex Pharmaceuticals Incorporated |
Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
|
|
NZ720282A
(en)
|
2008-02-28 |
2017-12-22 |
Vertex Pharma |
Heteroaryl derivatives as cftr modulators
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
HRP20180328T1
(hr)
|
2008-08-13 |
2018-04-20 |
Vertex Pharmaceuticals Inc. |
FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE
|
|
NZ592685A
(en)
|
2008-10-23 |
2013-04-26 |
Vertex Pharma |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
UA104876C2
(uk)
|
2008-11-06 |
2014-03-25 |
Вертекс Фармасьютікалз Інкорпорейтед |
Модулятори atф-зв'язувальних касетних транспортерів
|
|
EP2365972B1
(en)
|
2008-11-06 |
2014-12-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
|
SI2408750T1
(sl)
|
2009-03-20 |
2015-11-30 |
Vertex Pharmaceuticals Incorporated |
Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
|
|
WO2011029059A1
(en)
|
2009-09-04 |
2011-03-10 |
Mpex Pharmaceuticals, Inc. |
Use of aerosolized levofloxacin for treating cystic fibrosis
|
|
US20110098311A1
(en)
|
2009-10-22 |
2011-04-28 |
Vertex Pharmaceuticals Incorported |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
|
US8471029B2
(en)
|
2010-03-19 |
2013-06-25 |
Vertex Pharmaceutical Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
US20110251253A1
(en)
|
2010-03-25 |
2011-10-13 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
|
|
HRP20211752T1
(hr)
|
2010-04-07 |
2022-02-18 |
Vertex Pharmaceuticals Incorporated |
Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
|
|
HRP20160682T1
(hr)
|
2010-04-07 |
2016-07-29 |
Vertex Pharmaceuticals Incorporated |
Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
|
|
ES2608474T3
(es)
|
2010-04-22 |
2017-04-11 |
Vertex Pharmaceuticals Incorporated |
Proceso de producción de compuestos indol cycloalkylcarboxamido
|
|
CA2796642A1
(en)
|
2010-04-22 |
2011-10-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
|
CA2808501A1
(en)
|
2010-08-23 |
2012-03-01 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
|
|
RU2013113627A
(ru)
|
2010-08-27 |
2014-10-10 |
Вертекс Фармасьютикалз Инкорпорейтед |
Фармацевтическая композиция и ее введения
|
|
CN109559148A
(zh)
|
2011-01-04 |
2019-04-02 |
Aq株式会社 |
广告信息提供系统
|
|
HUE047354T2
(hu)
|
2011-05-18 |
2020-04-28 |
Vertex Pharmaceuticals Europe Ltd |
Ivacaftor deuterizált származékai
|
|
JP6063455B2
(ja)
|
2011-05-18 |
2017-01-18 |
コンサート ファーマシューティカルズ インコーポレイテッド |
重水素化されたイバカフトルの誘導体
|
|
WO2013038386A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Heterocyclic compounds for the treatment of cystic fibrosis
|
|
JP6014155B2
(ja)
|
2011-10-31 |
2016-10-25 |
ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． |
ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
|
|
IN2014KN00885A
(https=)
|
2011-11-08 |
2015-10-02 |
Vertex Pharma |
|
|
WO2013112804A1
(en)
|
2012-01-25 |
2013-08-01 |
Vertex Pharmaceuticals Incorporated |
Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
|
EP2819670A1
(en)
|
2012-02-27 |
2015-01-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administration thereof
|
|
AU2012377446A1
(en)
|
2012-04-20 |
2014-10-23 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
GB201207406D0
(en)
|
2012-04-27 |
2012-06-13 |
Glaxo Group Ltd |
Novel compounds
|
|
SG11201408284VA
(en)
|
2012-05-22 |
2015-02-27 |
Xenon Pharmaceuticals Inc |
N-substituted benzamides and their use in the treatment of pain
|
|
AU2013270681A1
(en)
|
2012-06-08 |
2014-12-18 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of CFTR -mediated disorders
|
|
WO2014014841A1
(en)
|
2012-07-16 |
2014-01-23 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
|
|
LT3470063T
(lt)
|
2012-11-02 |
2025-02-10 |
Vertex Pharmaceuticals Incorporated |
Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
|
|
MY183582A
(en)
|
2012-11-19 |
2021-02-26 |
Vertex Pharmaceuticals Europe Ltd |
Deuterated cftr potentiators
|
|
US9663508B2
(en)
|
2013-10-01 |
2017-05-30 |
Amgen Inc. |
Biaryl acyl-sulfonamide compounds as sodium channel inhibitors
|
|
JP6963896B2
(ja)
|
2013-11-12 |
2021-11-10 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
|
|
ES2885181T3
(es)
|
2014-04-15 |
2021-12-13 |
Vertex Pharma |
Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
|
|
TWI735416B
(zh)
|
2014-10-06 |
2021-08-11 |
美商維泰克斯製藥公司 |
囊腫纖維化症跨膜傳導調節蛋白之調節劑
|
|
KR20170063954A
(ko)
|
2014-10-07 |
2017-06-08 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
|
|
PT3221692T
(pt)
|
2014-11-18 |
2021-09-10 |
Vertex Pharma |
Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
|
|
JP6389904B2
(ja)
|
2015-01-29 |
2018-09-12 |
京セラ株式会社 |
測定装置およびセンサシステム
|
|
HK1249893A1
(zh)
|
2015-03-31 |
2018-11-16 |
Vertex Pharmaceuticals (Europe) Limited |
氘代vx-661
|
|
US9840513B2
(en)
|
2015-07-16 |
2017-12-12 |
Abbvie S.Á.R.L. |
Substituted tricyclics and method of use
|
|
UA124619C2
(uk)
|
2015-09-21 |
2021-10-20 |
Вертекс Фармасьютікалз (Юроп) Лімітед |
Введення дейтерованих підсилювачів cftr
|
|
HK1258473A1
(zh)
|
2015-09-25 |
2019-11-15 |
Vertex Pharmaceuticals (Europe) Limited |
氘代cftr增效剂
|
|
EP3854782A1
(en)
|
2016-03-30 |
2021-07-28 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
|
ES2946970T3
(es)
|
2016-03-31 |
2023-07-28 |
Vertex Pharma |
Regulador de conductancia transmembrana de moduladores de fibrosis quística
|
|
BR112018070747B1
(pt)
|
2016-04-07 |
2024-01-09 |
Proteostasis Therapeutics, Inc |
Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos
|
|
AU2017256172A1
(en)
|
2016-04-26 |
2018-09-06 |
AbbVie S.à.r.l. |
Modulators of cystic fibrosis transmembrane conductance regulator protein
|
|
US10138227B2
(en)
|
2016-06-03 |
2018-11-27 |
Abbvie S.Á.R.L. |
Heteroaryl substituted pyridines and methods of use
|
|
MA45397A
(fr)
|
2016-06-21 |
2019-04-24 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
|
US20180012171A1
(en)
|
2016-07-05 |
2018-01-11 |
Elie Massabki |
On-demand resource allocation
|
|
TW201811766A
(zh)
|
2016-08-29 |
2018-04-01 |
瑞士商諾華公司 |
N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
|
|
SI3519401T1
(sl)
|
2016-09-30 |
2022-01-31 |
Vertex Pharmaceuticals Incorporated |
Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja
|
|
US10399940B2
(en)
|
2016-10-07 |
2019-09-03 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
US9981910B2
(en)
|
2016-10-07 |
2018-05-29 |
Abbvie S.Á.R.L. |
Substituted pyrrolidines and methods of use
|
|
WO2018081381A1
(en)
|
2016-10-26 |
2018-05-03 |
Proteostasis Therapeutics, Inc |
Pyridazine derivatives, compositions and methods for modulating cftr
|
|
WO2018081378A1
(en)
|
2016-10-26 |
2018-05-03 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for modulating cftr
|
|
CA3041675A1
(en)
|
2016-10-26 |
2018-05-03 |
Proteostasis Therapeutics, Inc. |
N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
|
|
WO2018080591A1
(en)
|
2016-10-27 |
2018-05-03 |
Vertex Pharmaceuticals (Europe) Limited |
Methods of treatment with deuterated cftr potentiators
|
|
AU2017362350B2
(en)
|
2016-11-18 |
2021-12-23 |
Cystic Fibrosis Foundation |
Pyrrolopyrimidines as CFTR potentiators
|
|
CN110267948B
(zh)
*
|
2016-12-09 |
2023-12-08 |
弗特克斯药品有限公司 |
囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法
|
|
US10131670B2
(en)
|
2016-12-16 |
2018-11-20 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Bicyclic heteroaryl derivatives as CFTR potentiators
|
|
EP3558982A1
(en)
|
2016-12-20 |
2019-10-30 |
AbbVie S.À.R.L. |
Deuterated cftr modulators and methods of use
|
|
EP3565815B1
(en)
|
2017-01-07 |
2024-03-13 |
Fochon Pharmaceuticals, Ltd. |
Compounds as bcl-2-selective apoptosis-inducing agents
|
|
TW201831471A
(zh)
|
2017-02-24 |
2018-09-01 |
盧森堡商艾伯維公司 |
囊腫纖化症跨膜傳導調節蛋白的調節劑及其使用方法
|
|
WO2018183367A1
(en)
|
2017-03-28 |
2018-10-04 |
Van Goor Fredrick F |
Methods of treating cystic fibrosis in patients with residual function mutations
|
|
EP3601259B1
(en)
|
2017-03-30 |
2022-02-23 |
F. Hoffmann-La Roche AG |
Isoquinolines as inhibitors of hpk1
|
|
MA49061A
(fr)
|
2017-04-28 |
2021-04-21 |
Proteostasis Therapeutics Inc |
Dérivés 4-sulfonylaminocarbonylquinoline pour augmenter l'activité cftr
|
|
AU2018279646B2
(en)
|
2017-06-08 |
2023-04-06 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
|
CA3068609A1
(en)
|
2017-07-01 |
2019-01-10 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of cystic fibrosis
|
|
AU2018300150A1
(en)
|
2017-07-11 |
2020-01-30 |
Vertex Pharmaceuticals Incorporated |
Carboxamides as modulators of sodium channels
|
|
MA49631A
(fr)
|
2017-07-17 |
2020-05-27 |
Vertex Pharma |
Méthodes de traitement de la fibrose kystique
|
|
US20200171015A1
(en)
|
2017-07-17 |
2020-06-04 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
|
TWI799435B
(zh)
|
2017-08-02 |
2023-04-21 |
美商維泰克斯製藥公司 |
製備化合物之製程
|
|
US10988454B2
(en)
|
2017-09-14 |
2021-04-27 |
Abbvie Overseas S.À.R.L. |
Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
|
|
AU2018346602B2
(en)
|
2017-10-06 |
2024-10-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods for increasing CFTR activity
|
|
US10654829B2
(en)
|
2017-10-19 |
2020-05-19 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms and compositions of CFTR modulators
|
|
CA3082444A1
(en)
|
2017-12-01 |
2019-06-06 |
Vertex Pharmaceuticals Incorporated |
Processes for making modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2019113089A1
(en)
|
2017-12-04 |
2019-06-13 |
Vertex Pharmaceuticals Incorporated |
Compositions for treating cystic fibrosis
|
|
KR102716244B1
(ko)
|
2017-12-08 |
2024-10-14 |
버텍스 파마슈티칼스 인코포레이티드 |
낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
|
|
TWI810243B
(zh)
|
2018-02-05 |
2023-08-01 |
美商維泰克斯製藥公司 |
用於治療囊腫纖化症之醫藥組合物
|
|
AU2019222758B2
(en)
|
2018-02-15 |
2022-07-07 |
Vertex Pharmaceuticals Incorporated |
Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them
|
|
WO2019191620A1
(en)
|
2018-03-30 |
2019-10-03 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of modulators of cftr
|
|
US20210139514A1
(en)
|
2018-04-05 |
2021-05-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
EP3774825A1
(en)
*
|
2018-04-13 |
2021-02-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
|
|
PT3880197T
(pt)
|
2018-11-14 |
2023-05-09 |
Vertex Pharma |
Métodos de tratamento para a fibrose quística
|
|
CA3119656A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Macrocyclic compounds and their use in the treatment of disease
|
|
JP2022519301A
(ja)
|
2019-02-06 |
2022-03-22 |
ノバルティス アーゲー |
Ｎ－（ピリジン－２－イル）ピリジン－スルホンアミド誘導体及び疾患の処置におけるそれらの使用
|
|
US20220160705A1
(en)
|
2019-03-20 |
2022-05-26 |
Cornell University |
Methods for controlling prostaglandin-mediated biological processes
|
|
TWI848092B
(zh)
|
2019-04-03 |
2024-07-11 |
美商維泰克斯製藥公司 |
囊腫纖維化跨膜傳導調節蛋白調節劑
|
|
WO2020214921A1
(en)
|
2019-04-17 |
2020-10-22 |
Vertex Pharmaceuticals Incorporated |
Solid forms of modulators of cftr
|
|
WO2020242935A1
(en)
|
2019-05-29 |
2020-12-03 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|
|
CN114585628B
(zh)
|
2019-08-14 |
2024-03-26 |
弗特克斯药品有限公司 |
囊性纤维化跨膜传导调节因子的调节剂
|
|
TWI899097B
(zh)
|
2019-08-14 |
2025-10-01 |
美商維泰克斯製藥公司 |
製備cftr調節劑之方法
|
|
TWI867024B
(zh)
|
2019-08-14 |
2024-12-21 |
美商維泰克斯製藥公司 |
囊腫纖維化跨膜傳導調節蛋白之調節劑
|
|
CA3150162A1
(en)
|
2019-08-14 |
2021-02-18 |
Vertex Pharmaceuticals Incorporated |
Crystalline forms of cftr modulators
|
|
EP4058434A1
(en)
|
2019-11-12 |
2022-09-21 |
Genzyme Corporation |
6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
|
|
CN115003659B
(zh)
|
2019-11-12 |
2026-04-21 |
健赞公司 |
用于治疗由cftr活性缺乏介导的疾患的5元杂芳基氨基磺酰胺
|
|
CR20230120A
(es)
|
2020-08-07 |
2023-09-01 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
|
|
IL300413A
(en)
|
2020-08-13 |
2023-04-01 |
Vertex Pharma |
Crystal forms of CFTR modulators
|
|
US20230374038A1
(en)
|
2020-10-07 |
2023-11-23 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
MX2023004074A
(es)
|
2020-10-07 |
2023-07-05 |
Vertex Pharma |
Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica.
|
|
EP4225447A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
EP4225765A2
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
WO2022076626A1
(en)
|
2020-10-07 |
2022-04-14 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
EP4225446A1
(en)
|
2020-10-07 |
2023-08-16 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
|
AU2021397294A1
(en)
|
2020-12-10 |
2023-07-06 |
Vertex Pharmaceuticals Incorporated |
Methods of treatment for cystic fibrosis
|